Gilead Sciences Inc. GILD, +0.40% announced Friday that the U.S. Food and Drug Administration had approved the use Veklury (or remdesivir) for patients with severe kidney impairment, including dialysis patients. Veklury, the only COVID-antiviral approved for kidney disease patients at all stages, is now available. In the U.S. it is estimated that more than one in seven people, or 37 million Americans, have chronic kidney disease. They are at a higher risk of dying from COVID should they contract it. In late June, the European regulator gave a similar approval. Gilead stock is down 8% year-to-date, while S&P 500 Spx, +0.09% is up 17%.